Advertisement

MSMB Capital Management, a New York-based fund specializing in long-term strategic investments in health care and biotechnology, has made an unsolicited bid to acquire AMAG Pharmaceuticals Inc. (Nasdaq: AMAG) for $378 million, to block the proposed merger between AMAG and Allos Therapeutics.

Cambridge-based AMAG issued a statement saying its board of directors would evaluate the offer and make a recommendation to shareholders. The proposed deal between AMAG and Allos is worth $686 million and would give Allos a 39 percent stake in the new joint company.

SOURCE

Advertisement
Advertisement